Vaccine research combines the Canary pox vaccine ALVAC production of Sanofi-Aventis of France with the original AIDSVAX made VaxGen Inc. (license is held by the nonprofit organization Global Solutions for Infectious Diseases).
Was based HIV vaccine strains B and E are dominant in Thailand. In previous experiments, the vaccine is less effective if his or her own. The results of a recent study showed the vaccine was 31.2 percent effective in reducing the risk of contractingHIV.
According to Jerome olonel Kim, U.S. Military HIV Research Program, this is the first demonstration of an HIV vaccine capable of providing protection against HIV infection t.this is a very important scientific advances. This study gives hope that the possibility of making effective vaccines globally.
The vaccine was tested since early 2003, the volunteers made up of women and men aged 18-30 years and not infected with HIV. They are located in two provinces in Thailand, near Bangkok which has a high level of risk of HIV infection.
Half of the volunteers got the vaccine and some wore placebo (not containing vaccines). A total of 51 people from a total of 8197 people who get infected with HIV vaccines. As for the placebo group, from a total of 8198, as many as 74 people were infected. So there is a difference of about 23 people or 15%.
The discovery of this vaccine has not considered the perfect couple, still needs further stages to complete formulation of this vaccine, in order to obtain permission licensi drugs. However, this discovery is a step forward in the process of vaccine discovery that the disease was greatly feared.
-translated from pemudaindonesiabaru.blogspot.com -
0 komentar:
Posting Komentar